查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886062

全球免疫組織化學市場

Immunohistochemistry
出版日期: | 出版商: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球免疫組織化學市場預計2030年將達到45億美元。

全球免疫組織化學市場在2024年預計為30億美元，預計到2030年將達到45億美元，在分析期（2024-2030年）內複合年成長率（CAGR）為7.1%。本報告分析的細分市場之一－抗體市場，預期複合年成長率為7.2%，到分析期末將達到19億美元。設備細分市場預計在分析期間內複合年成長率為6.2%。

美國市場規模估計為8.247億美元，而中國市場預計將以6.6%的複合年成長率成長。

據估計，2024年美國免疫組織化學市場規模將達8.247億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到6.916億美元，在2024年至2030年的分析期內，複合年成長率（CAGR）為6.6%。其他值得關注的區域市場分析包括日本和加拿大，預計在分析期間內，兩國的複合年成長率分別為6.7%和5.8%。在歐洲，德國的複合年成長率預計約為5.8%。

全球免疫組織化學（IHC）市場—主要趨勢與促進因素概述

為什麼免疫組織化學（IHC）在疾病診斷和研究中變得越來越重要

免疫組織化學（IHC）利用標記抗體來檢測組織中的特定抗原，正日益成為疾病診斷、臨床研究和治療發展的重要工具。該技術結合了解剖學、免疫學和生物化學方法，能夠可視化特定蛋白質的分佈和定位，為細胞和組織生物學提供重要見解。 IHC廣泛應用於腫瘤學領域，用於檢測和分類癌細胞，使病理學家能夠診斷各種癌症類型、評估疾病嚴重程度並確定最佳治療策略。識別乳癌中的HER2、ER和PR以及肺癌中的PD-L1等生物標記的能力，可以指南標靶治療和個人化治療策略，使IHC成為現代病理學和精準醫學中不可或缺的工具。

慢性疾病（尤其是癌症）的日益普及是推動全球免疫組化（IHC）市場發展的主要因素之一。隨著全球癌症發生率的持續上升，人們對能夠區分癌症亞型並預測患者對特定治療方法的精準可靠的診斷工具的需求日益成長。 IHC 也被廣泛應用於神經病理學領域，用於識別阿茲海默症和帕金森氏症等神經退化性疾病，以及心血管疾病和感染疾病的研究。該技術能夠提供組織內蛋白質表達的空間和背景資訊，並且兼容多種組織樣本（包括切片檢查和手術標本），因此其應用範圍正在不斷擴大，涵蓋多個治療領域。隨著全球醫療保健系統越來越重視疾病早期檢測和個人化醫療，對先進 IHC 解決方案的需求預計將顯著成長。

哪些技術進步正在推動免疫組織化學的發展和廣泛應用？

技術創新徹底改變了免疫組織化學領域，使其更加精準、高效，並適用於更廣泛的應用。其中最具變革性的創新之一是自動化免疫組織化學平台的開發，該平台實現了從樣本製備、抗體孵育到洗滌和檢測的整個染色過程的自動化。自動化最大限度地減少了人為誤差，確保了結果的一致性，並縮短了周轉時間，使免疫組織化學更加可靠和可重複。羅氏BenchMark系列和Dako Autosterner等自動化免疫組織化學平台已成為高通量檢查室的必備工具，使其能夠在保持高診斷品質的同時高效處理大量檢體。將數位影像分析軟體整合到自動化平台中，進一步提高了免疫組織化學工作流程的效率，使病理學家能夠更精確地觀察、量化和解讀染色模式。

另一項重要進展是多重免疫組化（IHC）技術的發展，該技術能夠同時檢測單一組織切片上的多種生物標記。傳統的IHC技術每張切片只能分析一到兩種標記物，難以研究不同細胞類型和訊號路徑之間的複雜相互作用。多重IHC技術透過使用多種一抗（每種一抗都與不同的顯色或螢光報告分子偶聯）來克服這一局限性，從而在天然組織環境中可視化多種蛋白質。這項技術使研究人員能夠更深入研究腫瘤微環境、免疫細胞浸潤和生物標記共表達模式。諸如順序染色和條碼等新型多重技術的發展，進一步增強了IHC在研究和臨床應用中的效用，有助於識別預測性和預後性生物標記，並促進對疾病機制的理解。

先進檢測系統的引入，例如基於聚合物和奈米技術的檢測方法，正在提高免疫組化（IHC）的靈敏度和特異性。基於聚合物的檢測系統無需生物素，並減少了特異性結合和背景染色。同時，基於奈米技術的方法增強了訊號放大，從而能夠更清晰地檢測低表達蛋白。合成抗體和重組抗體的使用提高了IHC試劑的一致性和性能，確保了結果的可靠性和可重複性。此外，人工智慧（AI）和機器學習（ML）在數位病理學中的應用正在變革IHC結果的分析和解讀。 AI驅動的影像分析軟體能夠自動識別感興趣區域、量化染色強度並對組織樣本進行分類，從而減輕病理學家的工作負擔，並實現更準確、更標準化的評估。這些技術進步不僅增強了IHC的功能和可靠性，也拓展了其應用範圍，使其成為研究、診斷和個人化醫療領域的強大工具。

市場動態與監管標準如何影響免疫組織化學市場？

免疫組織化學市場受多種因素的複雜影響，包括市場力量、監管標準和醫療保健趨勢，這些因素共同影響著產品的開發、應用和商業化。其中一個關鍵的市場促進因素是慢性疾病（尤其是癌症）的日益普遍，這推動了對更有效的診斷和預後評估工具的需求。癌症是全球發病率和死亡率的主要原因，因此迫切需要準確的診斷方法來指導治療決策和監測疾病進展。免疫組織化學 (IHC) 廣泛應用於腫瘤學領域，用於檢測指示癌症類型、分級和潛在治療反應的生物標記。隨著標靶治療和免疫療法的日益普及，IHC 擴大被用於識別能夠從這些治療中獲益最大的患者，從而推動精準醫療的發展。此外，IHC 在心血管疾病、自體免疫和神經退化性疾病等領域的應用不斷擴展，也促進了市場成長。

監管標準和合規要求在塑造免疫組織化學市場方面也發揮關鍵作用。美國食品藥物管理局(FDA)、歐洲藥品管理局 (EMA) 和其他區域性監管機構等，已製定嚴格的指南，用於指導免疫組織化學 (IHC) 檢測的開發、測試和商業化，以確保其安全性、有效性和可靠性。遵守這些法規對於製造商獲得市場進入並維持醫療服務提供者和患者的信任至關重要。監管環境正在不斷發展，以應對免疫組織化學檢測的複雜性，尤其是在伴隨診斷方面。伴隨診斷用於識別最有可能對特定標靶治療產生反應的患者。伴隨診斷通常需要與相應的治療藥物共同開發和共同核准，這進一步增加了監管流程的複雜性。免疫組織化學檢測在個人化醫療中日益廣泛的應用，促使監管機構完善其指南，以確保免疫組織化學檢測能夠提供具有臨床意義的資訊，從而支持治療決策。

市場動態，包括製造商競爭、技術創新和醫療報銷政策，都會影響免疫組織化學市場。競爭格局的特點是，成熟的生命科學公司、診斷公司和專業試劑供應商都在致力於開發新的免疫組織化學解決方案，力求在提高靈敏度和特異性的同時，兼顧易用性。各公司透過產品創新、整合數位病理學和人工智慧技術，以及提供包含抗體、檢測系統和自動化平台在內的綜合性免疫組織化學解決方案來脫穎而出。醫療報銷政策和支付方的核保決策會影響免疫組織化學檢測的普及，因為報銷通常決定了這些產品的可近性和可負擔性。報銷環境因地區而異，並受到檢測的臨床效用、替代診斷方案的可用性以及整體醫療預算等因素的影響。對於在免疫組織化學市場中運作的公司而言，了解這些市場動態和監管標準至關重要，這有助於它們滿足全球患者和醫療服務提供者的未滿足診斷需求，並擴大市場佔有率。

推動免疫組織化學市場擴張的關鍵成長要素是什麼？

全球免疫組織化學市場成長主要受以下幾個關鍵因素驅動：癌症診斷需求的不斷成長、免疫組織化學技術的進步以及個人化醫療的日益普及。其中一個關鍵成長要素是癌症發生率的上升，這顯著增加了對能夠提供腫瘤生物學詳細資訊並輔助治療決策的診斷工具的需求。免疫組織化學廣泛應用於腫瘤學領域，用於檢測可用於腫瘤分類、預測疾病進展和識別潛在治療標靶的生物標記。標靶治療和免疫療法的日益普及也增加了對伴隨診斷的需求，其中許多伴隨診斷依賴免疫組織化學來確定生物標記的表達水平，並識別可能受益於特定治療的患者。隨著全球癌症負擔的持續加重和個人化醫療的日益普及，對先進免疫組織化學解決方案的需求預計將進一步成長。

另一個關鍵的成長要素是免疫組織化（IHC）技術的持續進步，這不斷拓展了該技術的功能和應用範圍。多重IHC、數位病理學和人工智慧驅動的影像分析等創新技術正在提高IHC的準確性、效率和臨床效用。多重IHC能夠同時檢測單一組織切片上的多種生物標記物，從而更全面地了解組織微環境，並有助於闡明複雜的生物學交互作用。數位病理學正在改變IHC結果的分析和解讀方式，使病理學家能夠在電腦螢幕上可視化組織樣本，進行定量分析，並與同事共用影像以進行遠端會診。人工智慧和機器學習的應用透過實現染色強度的自動量化、組織模式的分類和疾病預後的預測，進一步改進了IHC結果的解讀。這些技術進步使IHC更加強大和易用，從而促進了其在研究和臨床領域的應用。

人們對個人化醫療日益成長的興趣也推動了免疫組織化學市場的擴張。個人化醫療旨在根據每位患者獨特的基因和分子特徵最佳化治療策略。免疫組織化學在這過程中發揮關鍵作用，它能夠提供與疾病預後和治療反應相關的關鍵生物標記表達資訊。例如，免疫組織化學可用於檢測乳癌中HER2、肺癌中PD-L1和淋巴瘤中CD20的表達，從而指導標靶治療和免疫療法的應用。人們對個人化醫療日益成長的興趣正在推動新型免疫組織化學檢測方法和伴隨診斷技術的開發，以支持個人化的治療決策。將免疫組織化學與其他分子技術（例如次世代定序（NGS）和液態生物檢體）相結合，可以從分子和細胞層面更全面地了解疾病，進一步增強免疫組織化學在個人化醫療中的效用。

最後，免疫組織化學在研發領域的應用不斷擴展，也推動了市場成長。免疫組織化學廣泛應用於臨床前研究，用於分析蛋白質表現和定位、闡明疾病機制以及評估治療藥物對組織的影響。它也被用於臨床試驗，以評估新藥的動態並識別可作為替代終點的生物標記。隨著製藥和生技公司持續加大研發投入，對免疫組織化學試劑、抗體和檢測系統的需求預計將會增加。此外，免疫組織化學在腫瘤以外的其他疾病（例如神經退化性疾病、心血管疾病和感染疾病）研究中的應用日益廣泛，也擴大了市場範圍。在技​​術進步、應用領域不斷擴展以及對精準診斷和標靶治療日益重視的推動下，全球免疫組織化學市場預計將持續成長，製造商將不斷創新以滿足不斷變化的醫療需求，同時滿足腫瘤學、研究和個人化醫療等關鍵領域的持續需求。

部分：

依產品（抗體、器械、試劑、試劑盒）、應用（診斷、藥物檢測）、最終用途（醫院/診斷檢查室、研究機構、其他最終用途）分類

受訪公司範例

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Bio Sb, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • MilliporeSigma
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.

人工智慧整合

我們正在利用檢驗的專家內容和人工智慧工具，革新市場和競爭情報分析。

Market Glass, Inc. 並沒有採用查詢LLM 或產業專用的SLM 的常見做法，而是建立了一個由世界各地領域專家精心策劃的內容庫，其中包括影片文字稿、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

在最新發布的報告中，Market Glass, Inc. 將關稅對地理市場的影響納入考量，並根據公司總部所在國、製造地以及進出口（成品和OEM產品）情況，預測企業競爭格局的變化。這種複雜多變的市場現實將對競爭對手產生多方面的影響，包括銷貨成本增加、盈利下降和供應鏈重組，同時也會影響微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲
  • 亞太地區
  • 世界其他地區

第4章 競賽

簡介目錄
Product Code: MCP12536

Global Immunohistochemistry Market to Reach US$4.5 Billion by 2030

The global market for Immunohistochemistry estimated at US$3.0 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Antibodies, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Equipment segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$824.7 Million While China is Forecast to Grow at 6.6% CAGR

The Immunohistochemistry market in the U.S. is estimated at US$824.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$691.6 Million by the year 2030 trailing a CAGR of 6.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Global Immunohistochemistry (IHC) Market - Key Trends & Drivers Summarized

Why Is Immunohistochemistry (IHC) Gaining Prominence in Disease Diagnosis and Research?

Immunohistochemistry (IHC) is becoming a critical tool in disease diagnosis, clinical research, and therapeutic development due to its ability to detect specific antigens in tissues using labeled antibodies. This technique combines anatomical, immunological, and biochemical methods to visualize the distribution and localization of specific proteins, providing essential insights into cellular and tissue biology. IHC is widely used in oncology for the detection and classification of tumor cells, enabling pathologists to diagnose various types of cancers, assess the severity of the disease, and determine the best course of treatment. The ability to identify biomarkers such as HER2, ER, and PR in breast cancer, or PD-L1 in lung cancer, helps guide targeted therapies and personalized treatment strategies, making IHC an indispensable tool in modern pathology and precision medicine.

The growing prevalence of chronic diseases, particularly cancer, is one of the primary drivers of the global IHC market. As the global incidence of cancer continues to rise, there is an increasing need for accurate and reliable diagnostic tools that can differentiate between cancer subtypes and predict patient responses to specific therapies. IHC is also extensively used in neuropathology for the identification of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease, as well as in cardiovascular and infectious disease research. The technique’s ability to provide spatial and contextual information about protein expression in tissues, combined with its compatibility with a wide range of tissue samples, including biopsies and surgical specimens, is expanding its use across multiple therapeutic areas. As healthcare systems worldwide place a greater emphasis on early disease detection and personalized medicine, the demand for advanced IHC solutions is expected to increase significantly.

What Technological Advancements Are Driving the Evolution and Adoption of Immunohistochemistry?

Technological advancements are revolutionizing the field of immunohistochemistry, making it more accurate, efficient, and accessible for a broad range of applications. One of the most transformative innovations is the development of automated IHC platforms, which automate the entire staining process, from sample preparation and antibody incubation to washing and detection. Automation minimizes human error, ensures consistency, and reduces turnaround times, making IHC more reliable and reproducible. Automated IHC platforms such as the Roche BenchMark series and the Dako Autostainer have become essential tools in high-throughput laboratories, enabling the efficient processing of large numbers of samples while maintaining high diagnostic quality. The integration of digital imaging and analysis software with automated platforms is further enhancing the efficiency of IHC workflows, enabling pathologists to visualize, quantify, and interpret staining patterns with greater precision.

Another significant advancement is the development of multiplex IHC techniques, which allow for the simultaneous detection of multiple biomarkers on a single tissue section. Traditional IHC is limited to the analysis of one or two markers per slide, making it challenging to study complex interactions between different cell types or signaling pathways. Multiplex IHC overcomes this limitation by using multiple primary antibodies, each labeled with distinct chromogenic or fluorescent reporters, to visualize multiple proteins in their native tissue context. This capability is enabling researchers to investigate tumor microenvironments, immune cell infiltration, and biomarker co-expression patterns in greater detail. The development of novel multiplexing technologies, such as sequential staining and barcoding, is further enhancing the utility of IHC in research and clinical applications, supporting the identification of predictive and prognostic biomarkers and advancing our understanding of disease mechanisms.

The incorporation of advanced detection systems, such as polymer-based and nanotechnology-based detection methods, is also improving the sensitivity and specificity of IHC. Polymer-based detection systems eliminate the need for biotin, reducing non-specific binding and background staining, while nanotechnology-based methods enhance signal amplification, enabling the detection of low-abundance proteins with greater clarity. The use of synthetic and recombinant antibodies is improving the consistency and performance of IHC reagents, ensuring that the results are more reliable and reproducible. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in digital pathology is transforming the analysis and interpretation of IHC results. AI-driven image analysis software can automatically identify regions of interest, quantify staining intensity, and classify tissue samples, reducing the burden on pathologists and enabling more accurate and standardized assessments. These technological advancements are not only enhancing the capabilities and reliability of IHC but are also expanding its application possibilities, making it a powerful tool for research, diagnostics, and personalized medicine.

How Are Market Dynamics and Regulatory Standards Shaping the Immunohistochemistry Market?

The immunohistochemistry market is shaped by a complex interplay of market dynamics, regulatory standards, and healthcare trends that are influencing product development, adoption, and commercialization. One of the primary market drivers is the increasing prevalence of chronic diseases, particularly cancer, which is driving the demand for more effective diagnostic and prognostic tools. Cancer is a leading cause of morbidity and mortality worldwide, creating a significant need for accurate diagnostics that can guide treatment decisions and monitor disease progression. IHC is widely used in oncology to detect biomarkers that are indicative of cancer type, grade, and potential response to therapies. The rising adoption of targeted therapies and immunotherapies is further increasing the use of IHC to identify patients who are most likely to benefit from these treatments, supporting the trend toward precision medicine. Additionally, the expanding applications of IHC in areas such as cardiovascular, autoimmune, and neurodegenerative diseases are contributing to the growth of the market.

Regulatory standards and compliance requirements are also playing a critical role in shaping the immunohistochemistry market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other regional bodies have established stringent guidelines for the development, testing, and commercialization of IHC tests to ensure their safety, efficacy, and reliability. Compliance with these regulations is essential for manufacturers to gain market access and maintain the trust of healthcare providers and patients. The regulatory landscape is evolving to address the complexity of IHC tests, particularly in the context of companion diagnostics, which are used to identify patients who are most likely to respond to specific targeted therapies. Companion diagnostics often require co-development and simultaneous approval with the corresponding therapeutic agent, making the regulatory pathway more complex. The growing use of IHC in personalized medicine is encouraging regulatory agencies to refine their guidelines to ensure that IHC tests provide clinically meaningful information that can support treatment decisions.

Market dynamics such as competition among manufacturers, technological innovation, and healthcare reimbursement policies are also influencing the immunohistochemistry market. The competitive landscape is characterized by the presence of established life sciences companies, diagnostic firms, and specialized reagent providers, each striving to develop novel IHC solutions that offer enhanced sensitivity, specificity, and ease of use. Companies are differentiating themselves through product innovation, the integration of digital pathology and AI technologies, and the ability to provide comprehensive IHC solutions that include antibodies, detection systems, and automated platforms. Healthcare reimbursement policies and coverage decisions by payers are impacting the adoption of IHC tests, as reimbursement often determines the accessibility and affordability of these products. Reimbursement environments vary significantly across regions and are influenced by factors such as the clinical utility of the test, the availability of alternative diagnostic options, and the overall healthcare budget. Navigating these market dynamics and regulatory standards is essential for companies operating in the immunohistochemistry market as they seek to expand their presence and address the unmet diagnostic needs of patients and healthcare providers worldwide.

What Are the Key Growth Drivers Fueling the Expansion of the Immunohistochemistry Market?

The growth in the global immunohistochemistry market is driven by several key factors, including the increasing demand for cancer diagnostics, advancements in IHC technology, and the growing adoption of personalized medicine. One of the primary growth drivers is the rising incidence of cancer, which is creating a significant need for diagnostic tools that can provide detailed information about tumor biology and guide treatment decisions. IHC is widely used in oncology for the detection of biomarkers that can classify tumors, predict disease progression, and identify potential therapeutic targets. The growing use of targeted therapies and immunotherapies is increasing the demand for companion diagnostics, many of which rely on IHC to determine biomarker expression levels and identify patients who are likely to benefit from specific treatments. As the global burden of cancer continues to rise and as the adoption of personalized medicine increases, the demand for advanced IHC solutions is expected to grow.

Another significant growth driver is the ongoing advancement of IHC technology, which is expanding the capabilities and applications of the technique. Innovations such as multiplex IHC, digital pathology, and AI-driven image analysis are enhancing the accuracy, efficiency, and clinical utility of IHC. Multiplex IHC enables the simultaneous detection of multiple biomarkers on a single tissue section, providing a more comprehensive view of the tissue microenvironment and supporting the investigation of complex biological interactions. Digital pathology is transforming the way IHC results are analyzed and interpreted, allowing pathologists to visualize tissue samples on a computer screen, perform quantitative analysis, and share images with colleagues for remote consultation. The use of AI and machine learning is further enhancing the interpretation of IHC results by enabling automated quantification of staining intensity, classification of tissue patterns, and prediction of disease outcomes. These technological advancements are making IHC more powerful and accessible, supporting its adoption in both research and clinical settings.

The increasing focus on personalized medicine is also fueling the expansion of the immunohistochemistry market. Personalized medicine aims to tailor treatment strategies to individual patients based on their unique genetic and molecular profiles. IHC plays a critical role in this approach by providing information on the expression of key biomarkers that are associated with disease prognosis and response to treatment. For example, IHC is used to detect the expression of HER2 in breast cancer, PD-L1 in lung cancer, and CD20 in lymphoma, guiding the use of targeted therapies and immunotherapies. The growing emphasis on personalized medicine is encouraging the development of new IHC assays and companion diagnostics that can support individualized treatment decisions. The integration of IHC with other molecular techniques, such as next-generation sequencing (NGS) and liquid biopsy, is further enhancing its utility in personalized medicine by providing a more comprehensive view of the disease at both the molecular and cellular levels.

Lastly, the expanding applications of immunohistochemistry in research and drug development are contributing to the growth of the market. IHC is widely used in preclinical research to study protein expression and localization, investigate disease mechanisms, and evaluate the effects of potential therapeutic agents on tissues. The technique is also used in clinical trials to assess the pharmacodynamics of new drugs and to identify biomarkers that can serve as surrogate endpoints. As pharmaceutical and biotechnology companies continue to invest in research and development, the demand for IHC reagents, antibodies, and detection systems is expected to rise. Additionally, the increasing use of IHC in disease research beyond oncology, such as in neurodegenerative diseases, cardiovascular disorders, and infectious diseases, is expanding the market’s reach. As demand from key sectors such as oncology, research, and personalized medicine continues to rise, and as manufacturers innovate to meet evolving healthcare needs, the global immunohistochemistry market is expected to witness sustained growth, driven by advancements in technology, expanding applications, and the increasing emphasis on precision diagnostics and targeted therapies.

SCOPE OF STUDY:

The report analyzes the Immunohistochemistry market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Antibodies, Equipment, Reagents, Kits); Application (Diagnostics, Drug Testing); End-Use (Hospitals & Diagnostic Laboratories, Research Institutes, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 31 Featured) -

  • Abcam PLC
  • Agilent Technologies, Inc.
  • Bio Sb, Inc.
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • MilliporeSigma
  • PerkinElmer, Inc.
  • Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • Global Economic Update
    • Immunohistochemistry - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Cancer Diagnostics Drives Growth in Immunohistochemistry Market
    • Expansion of Research in Molecular Pathology Spurs Adoption of Immunohistochemistry Techniques
    • Growth in Focus on Targeted Therapies and Precision Medicine Expands Addressable Market for IHC
    • Role of Immunohistochemistry in Biomarker Detection and Cancer Subtyping Strengthens Business Case for Adoption
    • Growth in Use of IHC for Neurological and Infectious Disease Research Expands Market Opportunities
    • Technological Integration for Multiplexed IHC and Digital Pathology Expands Market Potential
    • Increasing Focus on IHC for Companion Diagnostics in Oncology Expands Addressable Market
    • Role of IHC in Enhancing Tissue-based Diagnostics and Personalized Medicine Strengthens Market Demand
    • Growth in Use of Immunohistochemistry in Drug Development and Clinical Trials Expands Market Reach
    • Growth in Use of IHC for Infectious Disease Detection and Surveillance Fuels Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Immunohistochemistry Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Drug Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Drug Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals & Diagnostic Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals & Diagnostic Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Immunohistochemistry by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Immunohistochemistry Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Immunohistochemistry by Product - Antibodies, Equipment, Reagents and Kits Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Immunohistochemistry by Product - Percentage Breakdown of Value Sales for Antibodies, Equipment, Reagents and Kits for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by Application - Diagnostics and Drug Testing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Immunohistochemistry by Application - Diagnostics and Drug Testing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Immunohistochemistry by Application - Percentage Breakdown of Value Sales for Diagnostics and Drug Testing for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Immunohistochemistry by End-Use - Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Immunohistochemistry by End-Use - Percentage Breakdown of Value Sales for Hospitals & Diagnostic Laboratories, Research Institutes and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION